Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

FDA approval sets up BMS’s Sotyktu as oral therapy of choice in psoriasis

Deucravacitinib safety, near biologic-like efficacy position first-in-class TYK2 inhibitor to supplant Otezla

By Stephen Hansen, Associate Editor
September 10, 2022 4:19 PM UTC
Updated on Sep 13, 2022 at 12:15 AM UTC

Strong efficacy data and a clean label put Bristol Myers’ Sotyktu deucravacitinib in pole position to quickly become the oral standard of care for plaque psoriasis.

Late Friday, FDA approved the first-in-class TYK2 inhibitor to treat moderate-to-severe plaque psoriasis, making it the second oral therapy approved for the indication after Otezla apremilast. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.

BCIQ Target Profiles

Tyrosine kinase 2 (TYK2)